700 patients110,866 observations180 daysLIVE

Patient P-02123

Synthetic patientMETA-24 · Day 166 · 35–44 · F · baseline S03Open companion preview
Therapy response
Improving
Tolerance
Stable
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
76%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 META-24 startedBaseline state S03
  2. Day 37 Trajectory diverged from predictionObserved response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 37.

Primary contributors, last 14 days
  • Treatment adherence-11
  • GI instability+10
  • Inflammatory activity+10
  • Toxicity-3

What helped?

No interventions yet.

    LIFE OS recommendation
    GI Support Protocol GI-04
    65%
    probability of meaningful tolerance improvement
    • 284 similar trajectories
    • 89% showed improvement
    • median effect visible after 8 days

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Autonomic recovery 65
      • WearableResting HR 76 bpm
      • Wearable462 steps/day
      • WearableShort sleep window
    • Butyrate / short-chain fatty acid production 55
      • MicrobiomeButyrate capacity 30/100
      • Daily logFibre intake low in recent food logs
    • Mucosal barrier integrity 50
      • DNAFUT2 non-secretor lowers mucosal fucosylation
      • Daily logGI symptom score 73 and rising
    • Inflammatory signalling 50
      • DNAIL6 -174 variant raises baseline inflammatory tone
      • BloodInflammatory load index 66
    • Drug metabolism and exposure 20
      • BloodToxicity index 48
    DNA
    Fictional pharmacogenomic panel
    • FUT2 rs601338 AA (non-secretor)
      Reduced mucosal fucosylation
    • IL6 -174 G/C
      Higher inflammatory tone
    • CYP2D6 Intermediate metabolizer
      Expected exposure
    • MTHFR C677T
      Reduced folate turnover
    Microbiome
    Shannon diversity 2.4 · butyrate capacity 30/100
    • Akkermansia muciniphilaNormal
    • Faecalibacterium prausnitziiNormal
    • Bacteroides fragilisNormal
    • Bifidobacterium longumNormal
    • EnterobacteriaceaeNormal
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    51 ms
    Sleep
    6.5 h
    Steps
    803
    Resting HR
    74 bpm
    Daily log: GI score 73, nutritional resilience 36, adherence 63.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
    • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
    • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
    • Eat slowly and stop at comfortable fullness — smaller volume, more often
    What to do
    • Track each bowel movement today: time, stool form, urgency, overnight waking
    • A 15-minute walk after lunch
    • Protect a 7.5-hour sleep window; screens off 30 minutes before
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the dose at the same time relative to your evening meal
    • Electrolyte solution, one sachet after any loose stool
    • Fictional demo item: oral nutrition supplement with lunch

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0236747%S0367
    P-0244447%S0759
    P-0247246%S1460
    P-0220545%S2057
    P-0252143%S1453
    P-0204640%S1055
    P-0202539%S15CR-01improved61
    P-0211139%S2051
    P-0216538%S14ME-01improved59
    P-0231637%S14GI-04improved51
    P-0240137%S14GI-04improved49
    P-0208436%S11GI-04no change58